Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6074533 | 0.80 | GSK3B (0.42) | GSK3AGSK3BSMN1; SMN2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3844256 | 0.80 | GSK3A (0.39) | GSK3AGSK3BSMN1; SMN2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL7421856 | 0.76 | GSK3B (0.41) | GSK3AGSK3BSMN1; SMN2NPC1RAB9A | |
| Bromide SCHEMBL6009339 | 0.75 | GSK3B (0.43) | GSK3AGSK3BSMN1; SMN2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3845964 | 0.74 | GSK3B (0.42) | GSK3AGSK3BSMN1; SMN2NPC1RAB9A | |
| Bromide SCHEMBL6009289 | 0.72 | GSK3A (0.35) | GSK3AGSK3BSMN1; SMN2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3849010 | 0.65 | GSK3B (0.44) | GSK3AGSK3BSMN1; SMN2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3849540 | 0.64 | GSK3B (0.43) | GSK3AGSK3BSMN1; SMN2NPC1RAB9A | |
| Bromide SCHEMBL6009306 | 0.63 | MEN1 (0.39) | GSK3AGSK3BSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2949251 | 0.62 | TSHR (0.61) | GSK3BSMN1; SMN2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022721-B1 | Method and composition for rejuvenating cells, tissues, organs, hair and nails | ULRICH PETER C | 2006-04-04 | — | — | US | disclosed |
| EP-1368029-A4 | METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS | FARRINGTON PHARMACEUTICALS LLC (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050245512-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | ULRICH PETER C | 2005-11-03 | — | — | US | disclosed |
| US-6777557-B2 | Method and composition for rejuvenating cells, tissues organs, hair and nails | FARRINGTON PHARMACEUTICALS, LLC | 2004-08-17 | — | — | US | disclosed |
| EP-1368029-A2 | METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS | Farrington Pharmaceuticals, LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020188015-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-12 | — | — | US | disclosed |
| WO-2002062301-A2 | METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS | FARRINGTON PHARMACEUTICALS, LLC (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188015-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | TERT, TELO2, HKDC1 | GSK3A 2314/4885GSK3B 2693/4885SMN1; SMN2 2608/4885 |
| US-20050245512-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | TERT, TELO2, HKDC1 | GSK3A 2314/4885GSK3B 2693/4885SMN1; SMN2 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.